drugset / Trial / NCT00828919

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

NCT00828919

Completed 52 enrolled Pfizer
NaOpen-labelTreatment

Summary

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Timeline

Start
2003-03-07
Primary completion
2023-08-14
Completion
2023-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule Oral
Background Crizotinib Small molecule Oral

Indications